文献速递消化道肿瘤与早癌

胃癌中肿瘤激活的中性粒细胞通过GM-CSF-PD-L1通路促进免疫抑制与疾病进展

Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
PubMed 文献 · Gut · 2017-03-08

该研究对105例胃癌患者样本进行流式细胞分析,发现肿瘤浸润中性粒细胞呈活化CD54+表型并高表达PD-L1,其水平与疾病进展及患者生存降低相关。肿瘤来源GM-CSF经JAK-STAT3通路诱导中性粒细胞PD-L1表达,活化的PD-L1+中性粒细胞在体外抑制T细胞免疫、在体内促进胃癌生长进展,阻断中性粒细胞PD-L1可逆转该效应。

要点

  • 胃癌患者肿瘤内中性粒细胞浸润显著增高,呈活化CD54+表型并高表达PD-L1。
  • 肿瘤浸润中性粒细胞PD-L1与CD54水平显著相关,PD-L1+中性粒细胞与疾病进展及生存降低相关。
  • 肿瘤来源GM-CSF经JAK-STAT3通路诱导中性粒细胞PD-L1表达,阻断PD-L1可逆转其免疫抑制及促肿瘤作用。

核心结论

  • 研究揭示了胃癌中肿瘤激活中性粒细胞表达PD-L1的新机制,并为GM-CSF-PD-L1通路用于预防和治疗胃癌免疫耐受提供功能证据。

研究设计与样本

  • 对105例胃癌患者样本进行流式细胞分析,检测中性粒细胞水平与表型。
  • 采用log-rank检验绘制Kaplan-Meier曲线分析总生存。
  • 分离中性粒细胞与T细胞,进行体外及体内调控与功能实验。

主要发现

  • 胃癌患者肿瘤内中性粒细胞浸润显著增高,肿瘤浸润中性粒细胞呈活化CD54+表型并高表达免疫抑制分子PD-L1。
  • 肿瘤激活的中性粒细胞寿命延长并强表达PD-L1,其表型与胃癌中状态相似,肿瘤浸润中性粒细胞PD-L1与CD54水平间存在显著相关。
  • 肿瘤内PD-L1+中性粒细胞与疾病进展及胃癌患者生存降低相关。
  • 肿瘤来源GM-CSF经JAK-STAT3信号通路激活中性粒细胞并诱导其PD-L1表达。
  • 活化的PD-L1+中性粒细胞在体外有效抑制正常T细胞免疫,在体内促进人胃癌生长与进展,阻断这些中性粒细胞上的PD-L1可逆转该效应。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Neutrophils are prominent components of solid tumours and exhibit distinct phenotypes in different tumour microenvironments. However, the nature, regulation, function and clinical relevance of neutrophils in human gastric cancer (GC) are presently unknown. DESIGN: Flow cytometry analyses were performed to examine levels and phenotype of neutrophils in samples from 105 patients with GC. Kaplan-Meier plots for overall survival were performed using the log-rank test. Neutrophils and T cells were isolated, stimulated and/or cultured for in vitro and in vivo regulation and function assays. RESULTS: Patients with GC showed a significantly higher neutrophil infiltration in tumours. These tumour-infiltrating neutrophils showed an activated CD54+ phenotype and expressed high level immunosuppressive molecule programmed death-ligand 1 (PD-L1). Neutrophils activated by tumours prolonged their lifespan and strongly expressed PD-L1 proteins with similar phenotype to their status in GC, and significant correlations were found between the levels of PD-L1 and CD54 on tumour-infiltrating neutrophils. Moreover, these PD-L1+ neutrophils in tumours were associated with disease progression and reduced GC patient survival. Tumour-derived GM-CSF activated neutrophils and induced neutrophil PD-L1 expression via Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) signalling pathway. The activated PD-L1+ neutrophils effectively suppressed normal T-cell immunity in vitro and contributed to the growth and progression of human GC in vivo; the effect could be reversed by blocking PD-L1 on these neutrophils. CONCLUSIONS: Our results illuminate a novel mechanism of PD-L1 expression on tumour-activated neutrophils in GC, and also provide functional evidence for these novel GM-CSF-PD-L1 pathways to prevent, and to treat this immune tolerance feature of GC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Wang TT, Zhao YL, Peng LS, et al. Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway. Gut. 2017. PMID: 28274999. doi:10.1136/gutjnl-2016-313075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。